CA3223889A1 - Pharmaceutical compositions of an epidermal growth factor receptor inhibitor - Google Patents

Pharmaceutical compositions of an epidermal growth factor receptor inhibitor Download PDF

Info

Publication number
CA3223889A1
CA3223889A1 CA3223889A CA3223889A CA3223889A1 CA 3223889 A1 CA3223889 A1 CA 3223889A1 CA 3223889 A CA3223889 A CA 3223889A CA 3223889 A CA3223889 A CA 3223889A CA 3223889 A1 CA3223889 A1 CA 3223889A1
Authority
CA
Canada
Prior art keywords
composition
oral dosage
dosage form
weight
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223889A
Other languages
English (en)
French (fr)
Inventor
Caitlin N. Kinkema
Debra L. Mazaik
Clare Aubrey Medendorp
Onkar Shripad VAZE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of CA3223889A1 publication Critical patent/CA3223889A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3223889A 2021-06-23 2022-06-22 Pharmaceutical compositions of an epidermal growth factor receptor inhibitor Pending CA3223889A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214099P 2021-06-23 2021-06-23
US63/214,099 2021-06-23
PCT/US2022/034433 WO2022271765A1 (en) 2021-06-23 2022-06-22 Pharmaceutical compositions of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
CA3223889A1 true CA3223889A1 (en) 2022-12-29

Family

ID=82608194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223889A Pending CA3223889A1 (en) 2021-06-23 2022-06-22 Pharmaceutical compositions of an epidermal growth factor receptor inhibitor

Country Status (9)

Country Link
US (1) US20240293323A1 (https=)
EP (1) EP4358942A1 (https=)
JP (1) JP2024525206A (https=)
CN (1) CN117835970A (https=)
AR (1) AR126195A1 (https=)
CA (1) CA3223889A1 (https=)
IL (1) IL309447A (https=)
TW (1) TW202317120A (https=)
WO (1) WO2022271765A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523506A (ja) * 2021-06-23 2024-06-28 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の塩及び結晶形態
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂
WO2024249660A1 (en) * 2023-05-31 2024-12-05 Amgen Inc. Compositions comprising sotorasib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
MX392941B (es) * 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
JP2024523506A (ja) * 2021-06-23 2024-06-28 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の塩及び結晶形態

Also Published As

Publication number Publication date
CN117835970A (zh) 2024-04-05
IL309447A (en) 2024-02-01
US20240293323A1 (en) 2024-09-05
TW202317120A (zh) 2023-05-01
EP4358942A1 (en) 2024-05-01
JP2024525206A (ja) 2024-07-10
WO2022271765A1 (en) 2022-12-29
AR126195A1 (es) 2023-09-27

Similar Documents

Publication Publication Date Title
US20240293323A1 (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
EP3089741B1 (en) Pharmaceutical compositions comprising azd9291
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
US20080026059A1 (en) Methods of Reducing Degradant Formation in Pharmaceutical Compositions of Varenicline
CN104936589A (zh) 具有改善的生物利用度的药物组合物
ZA200703866B (en) Pharmaceutical formulation containing a release rate controlling compositions
JP5775085B2 (ja) ｃ−ＭＥＴキナーゼ阻害剤の製剤
JP6814886B2 (ja) ベンゾイミダゾール誘導体を含む新規な製剤
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
US20220062263A1 (en) Crystalline forms and processes of lenvatinib besylate
KR20260029301A (ko) 골수성 키놈 억제제의 고체 분산물 및 그를 포함하는 제약 조성물
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
WO2021220295A1 (en) Immediate release pharmaceutical compositions comprising palbociclib
JP7585043B2 (ja) レナリドミドを含む医薬組成物
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
TW202444365A (zh) 改良之卡博替尼組合物及其使用方法
KR101068475B1 (ko) 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
HK40104279A (zh) 表皮生长因子受体抑制剂的药物组合物
RU2857663C2 (ru) Фармацевтическая композиция, содержащая пимитеспиб
US20070299054A1 (en) Oral pharmaceutical composition of a poorly water-soluble active agent
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib
CN119365195A (zh) 含有匹米替比的医药组合物
WO2007147873A1 (en) Oral pharmaceutical composition of a poorly water-soluble active substance
HK1228245B (en) Pharmaceutical compositions comprising azd9291
WO2013139826A1 (en) Pharmaceutical compositions comprising imatinib

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250430

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430